Drugs / Kamlanoflast
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07396818 | Feb 2026 → Jan 2027 expected | amyotrophic lateral sclerosis | Inflammasome Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kamlanoflast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07396818 ↗ |
| Route | Oral | “Kamlanoflast is orally administered over 24 weeks.” NCT07396818 ↗ |